bladder cancer
Deadly cancers are being financially left behind, new research claims
May 1, 2025Research and Development Jude, Oncology, UK, bladder cancer, cancer research, charitable funding
New research has revealed that some of the UK’s most deadly and prevalent cancers receive the least amount of charitable …
University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients
January 14, 2025Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients
The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …
Johnson & Johnson receive MHRA approval for BALVERSA
November 8, 2024Research and Development J&J Innovative Medicine, Oncology, Urology, bladder cancer
BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment …
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
June 27, 2024Research and Development IDEAYA Biosciences, Oncology, bladder cancer, clinical trials, oncology
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
April 23, 2024Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …
FDA approves Balversa for bladder cancer treatment
January 22, 2024Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer
Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer
May 18, 2023Research and Development Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology
US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic …
Birmingham University & Nonacus to develop urine test for bladder cancer
July 1, 2021bladder cancer, cfdna, oncology
The University of Birmingham has partnered with Nonacus to develop a non-invasive test for bladder cancer. The test, which is …
Gilead’s bladder cancer drug gets FDA approval
April 15, 2021FDA, Gilead, bladder cancer, bladder cancer treatment, pharma, pharma news
The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).
Roche voluntarily withdraws Tecentriq’s US bladder cancer indication
March 8, 2021Sales and Marketing Cancer, Roche, bladder cancer, tecentriq
Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …
MSD’s Keytruda misses the mark at Phase 3 in advanced bladder cancer
June 11, 2020Research and Development MSD< Keytruda, bladder cancer, pharma, trial failure
MSD has announced the disappointing findings that its anti-PD-1 immunotherapy Keytruda (pembrolizumab), when used either alone or combined with chemotherapy, …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer
February 12, 2020Research and Development Astellas, Cancer, Seattle Genentics, bladder, bladder cancer, keytruda, monotherapy
Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer. The data …
MSD’s Keytruda chalks up bladder cancer approval in the US
January 9, 2020Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …
FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug
December 19, 2019Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer
The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …
